The multicenter CATCOVID trial for the treatment of severe COVID-19 courses enrolls the first patient at Leipzig University Hospital!
The aim of the CATCOVID trial is to increase the survival and healing chances of intensive care patients with a severe COVID-19 course of disease with the help of the active substance.
Our two HiGHmed partners Charité - Universitätsmedizin Berlin and the University Hospital of Würzburg, as well as our associated partner Unfallkrankenhaus Berlin (UKB), had joined forces with the Berlin Institute of Health (BIH) at Charité, Bayer and the University Hospital of Leipzig for a multi-site COVID-19 trial.
In close collaboration with HiGHmed e.V., the joint project application was submitted to the German Federal Ministry of Education and Research and ultimately received the appropriate funding.
Currently, the final preparations for the initiation of the trial are underway at the three other participating trial centers.
Click here for the official PR: https://bit.ly/3pg0RiR